Published in J Health Serv Res Policy on July 01, 2004
Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals. BMC Health Serv Res (2009) 0.75
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ (2002) 5.36
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health (2013) 4.22
A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet (2002) 3.26
A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res (2013) 2.59
Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ (2003) 2.50
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics (2013) 2.21
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ (2013) 2.21
Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy (2009) 1.94
Prevalence and nature of medication administration errors in health care settings: a systematic review of direct observational evidence. Ann Pharmacother (2013) 1.92
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health (2013) 1.89
Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart--Then Focus. J Antimicrob Chemother (2012) 1.86
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol (2010) 1.84
Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens (2003) 1.83
What do international pharmacoeconomic guidelines say about economic data transferability? Value Health (2010) 1.74
Antibiotic stewardship--more education and regulation not more availability? J Antimicrob Chemother (2009) 1.71
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health (2013) 1.67
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care (2013) 1.66
Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health (2012) 1.60
Estimation of central aortic pressure by SphygmoCor requires intra-arterial peripheral pressures. Clin Sci (Lond) (2003) 1.55
Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health (2011) 1.53
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Clin Ther (2013) 1.53
Amniocentesis and informed consent. Br Med J (Clin Res Ed) (1988) 1.52
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. J Med Econ (2013) 1.49
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med (2013) 1.44
A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health (2003) 1.43
Using evidence in the development of local health policies. Some evidence from the United Kingdom. Int J Technol Assess Health Care (2002) 1.35
Causes of medication administration errors in hospitals: a systematic review of quantitative and qualitative evidence. Drug Saf (2013) 1.29
Can economic evaluations be made more transferable? Eur J Health Econ (2005) 1.27
Best practice in undertaking and reporting health technology assessments. Working group 4 report. Int J Technol Assess Health Care (2002) 1.25
Antibiotic stewardship programmes--what's missing? J Antimicrob Chemother (2010) 1.24
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
Economic evaluation of health interventions. BMJ (2008) 1.19
Orphan drugs policies: a suitable case for treatment. Eur J Health Econ (2014) 1.17
EBM, HTA, and CER: clearing the confusion. Milbank Q (2010) 1.15
Improving medical device regulation: the United States and Europe in perspective. Milbank Q (2014) 1.13
Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) (2007) 1.12
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health (2007) 1.08
Retaining, and enhancing, the QALY. Value Health (2009) 1.08
Health economic evaluation: important principles and methodology. Laryngoscope (2013) 1.05
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health (2005) 1.05
Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics (2011) 1.03
The drug budget silo mentality in Europe: an overview. Value Health (2003) 1.02
The effectiveness and cost-effectiveness of respite for caregivers of frail older people. J Am Geriatr Soc (2007) 1.01
A research agenda for economic evaluation of substance abuse services. J Subst Abuse Treat (2005) 1.00
Applying health economics for policy decision making: do devices differ from drugs? Europace (2011) 0.99
Guidelines for completing the EURONHEED transferability information checklists. Eur J Health Econ (2008) 0.99
Value-based differential pricing: efficient prices for drugs in a global context. Health Econ (2013) 0.97
Operationalizing value-based pricing of medicines : a taxonomy of approaches. Pharmacoeconomics (2013) 0.95
Moving the QALY forward: rationale for change. Value Health (2009) 0.95
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ (2013) 0.93
Economics methods in Cochrane systematic reviews of health promotion and public health related interventions. BMC Med Res Methodol (2006) 0.93
Medical technology as a key driver of rising health expenditure: disentangling the relationship. Clinicoecon Outcomes Res (2013) 0.92
Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics (2009) 0.92
Impact of interventions designed to reduce medication administration errors in hospitals: a systematic review. Drug Saf (2014) 0.92
Terminal digit preference and single-number preference in the Syst-Eur trial: influence of quality control. Blood Press Monit (2002) 0.91
Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol (2011) 0.91
Another special relationship? Interactions between health technology policies and health care systems in the United States and the United Kingdom. J Health Polit Policy Law (2011) 0.91
The desirability and feasibility of economic studies of drugs post-launch. Eur J Health Econ (2006) 0.89
Issues for countries considering introducing the "fourth hurdle": the case of Hungary. Int J Technol Assess Health Care (2004) 0.89
Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care (2015) 0.88
Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med (2003) 0.88
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Eff Resour Alloc (2013) 0.88
Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? Eur J Health Econ (2012) 0.88
The lag between effectiveness and cost-effectiveness evidence of new drugs. Implications for decision-making in health care. Eur J Health Econ (2003) 0.87
OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol (2003) 0.86
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ (2008) 0.85
The economics of gene therapy and of pharmacogenetics. Value Health (2002) 0.85
Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study. Value Health (2007) 0.85
Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making (2005) 0.84
Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care (2011) 0.84
Health care resource use and stroke outcome. Multinational comparisons within the GAIN International trial. Int J Technol Assess Health Care (2003) 0.83
Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value. Health Aff (Millwood) (2013) 0.83
The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics (2005) 0.82
Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence. J Clin Oncol (2012) 0.82
New BMJ policy on economic evaluations. Response of NHS Economic Evaluation Database Research Team. BMJ (2003) 0.82
Retrospective analysis of medication incidents reported using an on-line reporting system. Pharm World Sci (2006) 0.81
Economic endpoints in clinical trials. Stat Methods Med Res (2004) 0.81
Evolution of the health economics of cervical cancer vaccination. Vaccine (2008) 0.81
Carotid endarterectomy for treatment of in-stent restenosis. J Vasc Surg (2011) 0.81
Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff (Millwood) (2011) 0.80
The European Network of Health Economic Evaluation Databases (EURO NHEED) Project. Eur J Health Econ (2004) 0.80
Incorporating economic analysis in evidence-based guidelines for mental health: the profile approach. J Ment Health Policy Econ (1999) 0.80
Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics (2004) 0.80
Transferability of health technology assessment reports in Latin America: an exploratory survey of researchers and decision makers. Int J Technol Assess Health Care (2012) 0.80
Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study. J Popul Ther Clin Pharmacol (2015) 0.80
The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project. Pharmacoeconomics (2005) 0.79
Alternative approaches for assessing the socioeconomic benefits of medical devices: a systematic review. Expert Rev Med Devices (2015) 0.79
A review of health technology appraisals: case studies in oncology. Int J Technol Assess Health Care (2012) 0.79
Regulatory issues and economic efficiency. J Rheumatol Suppl (2003) 0.78
Prescribing incentive schemes : a useful approach? Appl Health Econ Health Policy (2005) 0.78
Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences. Expert Rev Pharmacoecon Outcomes Res (2013) 0.78
Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics (2010) 0.78
Better analysis for better decisions: has pharmacoeconomics come of age? Pharmacoeconomics (2006) 0.78